383 results on '"Pitteri, Sharon J."'
Search Results
2. Identification and characterization of intact glycopeptides in human urine
3. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer
4. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas
5. Establishing and Characterizing the Molecular Profiles, Cellular Features, and Clinical Utility of a Patient-Derived Xenograft Model Using Benign Prostatic Tissues
6. Guanylate-binding protein 1 modulates proteasomal machinery in ovarian cancer
7. Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry
8. Measuring the multifaceted roles of mucin-domain glycoproteins in cancer
9. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
10. Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera.
11. How many human proteoforms are there?
12. Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer
13. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer
14. Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer
15. Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer
16. Plectin is a regulator of prostate cancer growth and metastasis
17. Guanylate Binding Protein 1 (GBP1) modulates proteasomal machinery in ovarian cancer
18. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
19. Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
20. Enrichment of Intact Glycopeptides Using Strong Anion Exchange and Electrostatic Repulsion Hydrophilic Interaction Chromatography
21. Correction to “Tumor Cell-Derived Extracellular Vesicle-Coated Nanocarriers: An Efficient Theranostic Platform for the Cancer-Specific Delivery of Anti-miR-21 and Imaging Agents”
22. Postmenopausal estrogen and progestin effects on the serum proteome
23. Siglec-7/9 are novel immune checkpoints for prostate cancer
24. Data from Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women
25. Data from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
26. Supplementary Figure 4 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
27. Supplementary Figure 6 from Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women
28. Supplementary Table 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
29. Supplementary Figure 3 from Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women
30. Supplementary Figure 2 from Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women
31. Supplementary Table 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
32. Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
33. Supplementary Figure 4 from Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women
34. Supplementary Figure 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
35. Supplementary Figure 5 from Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women
36. Supplementary Figure 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
37. Supplementary Figure 1 from Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women
38. Supplementary Figure 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
39. Supplementary Table 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
40. Supplementary Data from Multiomics Analysis of Spatially Distinct Stromal Cells Reveals Tumor-Induced O-Glycosylation of the CDK4–pRB Axis in Fibroblasts at the Invasive Tumor Edge
41. Data from Multiomics Analysis of Spatially Distinct Stromal Cells Reveals Tumor-Induced O-Glycosylation of the CDK4–pRB Axis in Fibroblasts at the Invasive Tumor Edge
42. Supplementary Table Legends 1-4, Figure Legends 1-6 from Tumor Microenvironment–Derived Proteins Dominate the Plasma Proteome Response during Breast Cancer Induction and Progression
43. Supplementary Table 2 from Concordant Release of Glycolysis Proteins into the Plasma Preceding a Diagnosis of ER+ Breast Cancer
44. Supplementary Figure 1 from Detection of Elevated Plasma Levels of Epidermal Growth Factor Receptor Before Breast Cancer Diagnosis among Hormone Therapy Users
45. Data from Tumor Microenvironment–Derived Proteins Dominate the Plasma Proteome Response during Breast Cancer Induction and Progression
46. Data from Autoantibody Signatures Involving Glycolysis and Splicesome Proteins Precede a Diagnosis of Breast Cancer among Postmenopausal Women
47. Supplementary Table 3 from Tumor Microenvironment–Derived Proteins Dominate the Plasma Proteome Response during Breast Cancer Induction and Progression
48. Supplementary Table 1 from Tumor Microenvironment–Derived Proteins Dominate the Plasma Proteome Response during Breast Cancer Induction and Progression
49. Supplementary Figure and Table Legend from Detection of Elevated Plasma Levels of Epidermal Growth Factor Receptor Before Breast Cancer Diagnosis among Hormone Therapy Users
50. Supplementary Table 1 from Detection of Elevated Plasma Levels of Epidermal Growth Factor Receptor Before Breast Cancer Diagnosis among Hormone Therapy Users
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.